培门冬酶/左旋门冬酰胺酶治疗结外NK/T细胞淋巴瘤的预后因素分析：多中心回顾性研究

OBJECTIVE: To explore the prognostic factors of extracellular NK/T cell lymphoma（ENKTL）treated with pegaspargase/L-asparaginase. METHODS: The clinical data of 656 ENKTL patients diagnosed at 11 medical centers in the Huaihai Lymphoma Working Group from March 2014 to April 2021 were retrospectively analyzed. The patients were randomly divided into two groups: a training set（460 cases）and a validation set（196 cases）at 7∶3, and the prognostic factors of the patients were analyzed. A prognostic scoring system was established, and the predictive performance of different models was compared. RESULTS: Patients' median age was 46（34, 57）years, with 456 males（69.5％）and 561 nasal involvement（85.5％）. 203 patients（30.9％）received a chemotherapy regimen based on L-asparaginase combined with anthracyclines, and the 5-year overall survival rate of patients treated with P-GEMOX regimen（pegaspargase+gemcitabine+oxaliplatin）was better than those treated with SMILE regimen（methotrexate+dexamethasone+cyclophosphamide+L-asparaginase+etoposide）（85.9％ vs 63.8％; P＝0.004）. The results of multivariate analysis showed that gender, CA stage, the Eastern Cooperative Oncology Group performance status（ECOG PS）score, HGB, and EB virus DNA were independent influencing factors for the prognosis of ENKTL patients（P<0.05）. In this study, the predictive performance of the prognostic factors is superior to the international prognostic index, Korean prognostic index, and prognostic index of natural killer lymphoma. CONCLUSION: Gender, CA stage, ECOG PS score, HGB, and EB virus DNA are prognostic factors for ENKTL patients treated with pegaspargase/L-asparaginase.